The Gastric Cancer Market is Expected to More Than Triple Over the Next Ten Years, Capturing Nearly $3.8 billion by 2023

BURLINGTON, Mass., Sept. 18, 2014 /PRNewswire/ -- Decision Resources Group finds that the gastric cancer market will grow exponentially from over $1.1 billion in 2013 to nearly $3.8 billion by 2023. Fuelling this growth will be the launch of five targeted therapies for unresectable locally advanced and metastatic gastric cancer. Eli Lilly's Cyramza, which was approved by the U.S. Food and Drug Administration in 2014, is the first targeted therapy to enter the second-line metastatic setting and thereby partially fulfills an unmet need. Nevertheless, considerable market opportunity remains for more effective, safe and tolerable therapies.

Other key findings from the Pharmacor report entitled Gastric Cancer:

• Use of predictive biomarkers: A number of drugs in early- and late-phase clinical development are targeting patient subpopulations that carry a specific biomarker – notably HER2 and c-Met. The emergence of Roche/Genentech/Chugai's HER2-targeted agents, Perjeta and Kadcyla, and Amgen's c-Met inhibitor rilotumumab will propel gastric cancer treatment toward more-personalized therapy.
• New market entrants for HER2-positive gastric cancer: Kadcyla and Perjeta will compete for a share of this small patient segment, making it a dynamic space dominated by the Roche HER2 franchise.
• Unmet needs: Interviewed experts stress that an urgent need remains for more-effective treatment options that can extend survival, especially for patients who are HER2-negative and thus not eligible for Herceptin.
• Second-line dynamics of Cyramza and Kadcyla: Interviewed experts expect that Cyramza will quickly become the treatment of choice in the second-line metastatic setting. However, Decision Resources Group expects that the launch of Kadcyla in this setting will be a major breakthrough in treatment, and that it will emerge as the second-line standard of care for HER2-positive gastric cancer patients who are refractory to Roche/Genentech/Chugai's Herceptin.

Comments from Decision Resources Group Analyst Sehrish Rafique, M.Sc., Ph.D.:

• "The failure of Roche/Genentech's MetMab has cast considerable doubt over whether or not c-Met inhibitors will be successful in gastric cancer. However, interviewed experts point out that c-Met positivity needs to be better defined in these trials and that perhaps these drugs benefit a smaller population of patients than originally anticipated."

• "The gastric cancer treatment algorithm is going to diversify over the coming years with more options becoming available for patients with unresectable or metastatic disease. Whilst many of these agents are adjuncts to chemotherapy, overall we will see a move away from chemotherapy alone being the mainstay treatment for gastric cancer to a more individualized approach."

About Decision Resources Group
Decision Resources Group offers best-in-class, high-value information and insights on critical issues within the healthcare industry. Clients rely on this analysis and data to make informed decisions. Find out more at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Christopher Comfort
Decision Resources Group
781-993-2597
[email protected]

Logo - http://photos.prnewswire.com/prnh/20130103/MM36768LOGO

SOURCE Decision Resources Group